ClinicalTrials.gg
RecruitingNCT07349303NEOPRIMEUpdated Aug 26, 2026

Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma

A Phase 2 interventional study of Pembrolizumab and Placebo in Melanoma (Skin Cancer), sponsored by Vastra Gotaland Region. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Vastra Gotaland Region · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies testing pembrolizumab in Melanoma — 20 open to participants now, 41 under way, 7 of them phase 3. pembrolizumab · Melanoma.

Planned enrollment
59th of 87
30 · median 53
Started
2026
with 4 others
Phase 2
49 of 87
12 open now
Primary completion
2029-05
later than 34 of 40 live
Registered
80th of 87
by date

Among the 87 studies testing pembrolizumab in Melanoma, this one is the 59th largest by planned enrollment, is one of 5 that started in 2026, is one of 49 in phase 2, reaches primary completion later than 34 of the 40 other live ones, and was the 80th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

20 of the 87 studies testing pembrolizumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing pembrolizumab in Melanoma, or all of them as a file.
02

Study summary

A phase II double-blind placebo-controlled randomized trial. Patients with a clinical suspicion of a thick primary melanoma without clinical suspicion or evidence of lymph-node engagement will undergo a 3 mm punch biopsy to verify the diagnosis and ascertain eligibility. Patients will receive 1 cycle of pembrolizumab 400 mg or placebo and 4 weeks later undergo a wide local excision and sentinel lymph node biopsy according to the national guideline recommendations .

The primary objective is to evaluate the pathological response of one cycle of neoadjuvant pembrolizumab in patients with biopsy-proven stage IIb/c melanoma. Secondary objectives include efficacy and safety analysis, as well as biomarker discovery.

03

Conditions studied

  • Melanoma (Skin Cancer)

Browse trials for

Keywords

  • IMMUNOTHERAPY
  • PRIMARY CUTANOUS MELANOMA
  • NEOPRIME trial
  • NEOADJUVANT TREATMENT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is ≥18 years.
  2. Signed .
  3. (ECOG) performance status of 0-1
  4. Histopathologically confirmed primary cutaneous melanoma stage IIb/c (Breslow >2.0 mm with ulceration OR Breslow >4.0mm without ulceration) with a minimum diameter of 5 mm not completely removed by the diagnostic
  5. Patient planned for wide local excision and sentinel lymph node biopsy
  6. Adequate organ function on blood test
  7. Female patient of should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  8. Female patients of childbearing potential must be willing to use an adequate method of , for the course of the study through 150 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
  9. Male patients of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 150 days after the last dose of study therapy. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

Exclusion criteria

Exclusion Criteria:

  1. of less than 3 years.
  2. Patients who are unable to undergo general anesthesia for any reason.
  3. Clinical or radiographic evidence of nodal, satellite, in-transit or distant
  4. Risk for developing in-operable disease due to study procedures as judged by study investigator
  5. Prior immunotherapy for any
  6. Use of four weeks before or after the last study treatment.
  7. History of severe reactions to monoclonal antibodies.
  8. Active disease or a documented history of autoimmune disease requiring systemic immunomodulatory treatment. Diabetes, rheumatoid arthritis, psoriasis, atopic dermatitis and hypothyroidism are excepted.
  9. A condition requiring systemic treatment with either (>10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  10. Concomitant therapy with any other anti-cancer therapy, concurrent medical conditions requiring use of immunosuppressive medications or use of other drugs.
  11. Has a known additional malignancy that is progressing or requires active treatment.
  12. Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of study drug.
  13. A history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate in the opinion of the treating investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Pembrolizumab

    Patients will receive one dose of intravenous pembrolizumab and then 4 weeks later undergo WLE and SLNB.

    Drug: Pembrolizumab

  • Placebo comparator
    Placebo

    Patients will receive one dose of intravenous placebo and then 4 weeks later undergo WLE and SLNB.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Pathological response rate

    Pathological response rate in the primary tumor according to adapted guidelines of the International Neoadjuvant Consortium (14) The pathological response will be described: * Complete pathological response (pCR) - 0% viable tumor cells in the surgical specimen * Near complete pathological response (near pCR) - ≤10% viable tumor * Partial pathological response (pPR) - \>10%-≤50% viable tumor * No pathological response (pNR) - \>50% viable tumor The proportion of patients with a pCR, near pCR or pPR will determine the pathological response rate.

    Time frame: 48 month

Secondary outcomes

  1. Frequency and severity of adverse events (AEs) and serious adverse events (SAEs)

    The proportion of patients with adverse events (AE) as described in CTCAE version 5.0, from the initiation of study treatment until 100 days after the end of treatment: 1. Proportion of patients with an AE by CTCAE term and grade. 2. Proportion of patients with grade 3/4 AEs by AE term. 3. The duration of events reported in (a) 4. Proportion of patients with requirement to delay surgery due to an AE. 5. Proportion of patients with a requirement to permanently discontinue study treatment due to an AE. 6. The proportion of patients with a requirement for oral or parenteral steroid treatment for immunology-related adverse events. 7. The proportion of patients with post-operative complications (e.g. seroma formation, wound infection or lymphoedema) and duration of events.

    Time frame: 48 month

  2. Feasibility of neoadjuvant therapy in stage II melanoma

    1. Proportion of eligible patients who consent to the study. 2. Proportion of included patients who complete all treatment according to protocol.

    Time frame: 48 month

  3. Sentinel lymph node positivity rate

    1. The proportion of patients undergoing a sentinel node biopsy who have a positive result in the lymph node. 2. The number of sentinel nodes identified and the number harvested. 3. The proportion of patients with a positive sentinel node biopsy who undergo completion lymph node dissection.

    Time frame: 48 month

  4. Local recurrence rate

    The proportion of patients after surgery with histologically confirmed diagnosis of local disease recurrence, as detected by the patient, on physical examination or during imaging surveillance.

    Time frame: 48 month

  5. Regional recurrence rate

    The proportion of patients after surgery with histologically confirmed diagnosis of regional disease recurrence, as detected by the patient, on physical examination or during imaging surveillance

    Time frame: 48 month

  6. Event free survival (EFS)

    The proportion of patients that did not undergo surgery or histologically confirmed diagnosis of disease recurrence (local, regional, and distant), as detected by the patient, on physical examination or during imaging surveillance, or death from any cause.

    Time frame: 48 month

  7. To assess recurrence free survival (RFS).

    The proportion of patients after surgery with histologically confirmed diagnosis of disease recurrence (local, regional, and distant), as detected by the patient, on physical examination or during imaging surveillance, or death from any cause.

    Time frame: 48 month

  8. Distant metastasis-free survival (DMFS)

    The proportion of patients after surgery with histologically confirmed diagnosis of disease distant recurrence, as detected by the patient, on physical examination or during imaging surveillance, or death from any cause.

    Time frame: 48 month

  9. Melanoma specific survival (MSS)

    The proportion of patients who die, from the initiation of study treatment to the date of death from melanoma.

    Time frame: 48 month

  10. Overall survival (OS)

    The proportion of patients who die, from the initiation of study treatment to the date of death from any cause.

    Time frame: 48 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2029, 40 months after the start.

Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 40 months is below that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jan 16, 2026
StartActual
Jan 15, 2026
Primary completionEst.
May 15, 2029
CompletionEst.
May 15, 2031
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07349303
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Jan 15, 2026
Primary completion
May 15, 2029 (estimated)
Completion
May 15, 2031 (estimated)
Last update
Aug 26, 2026

Study contacts

Roger Olofsson Bagge, Professor
Contact
roger.olofsson.bagge@vgregion.se
+46 31 3421000
Axel Nelson, MD, PhD
Contact
axel.nelson@vgregion.se

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion